Biotech Business - April 25, 2022
Ultimovacs receives Notice of Allowance on US Patent
Ultimovacs has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to grant formalities, it is expected that a patent will issue with a patent term up to at least June 2037. Ultimovacs has […]
Intellectual Property - April 20, 2022
Spago Nanomedical receives extended patent protection in Japan
Spago Nanomedical has received notice from the Japanese Patent Office (JPO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D. JPO has issued a Notice of Allowance which means the patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees. The […]
Intellectual Property - March 17, 2022
AstraZeneca reaches settlement agreement
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo […]
Intellectual Property - March 9, 2022
Sigrid Therapeutics granted European patent
Sigrid Therapeutics has announced that the European Patent Office has granted the company patent titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in […]
Intellectual Property - February 9, 2022
Salipro Biotech receives European patent
The European Patent Office has granted a further European patent to the company, entitled “Antigen and method for production thereof”. The granted European patent follows the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. “We’re excited about this important milestone that provides additional protection for our core […]
Intellectual Property - January 17, 2022
Targovax granted new patents
Targovax has announced that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively. The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma. “We are delighted that these patents have been granted, further strengthening Targovax’s intellectual property portfolio. The 30-month data from our ONCOS-102 […]
